CORONA Remedies Limited share price
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.Read more
HealthcareDrug Manufacturers - GeneralNSE: CORONAISIN INE02ZQ01018
16 Oct 2026, 3:30 PM IST₹2,003.90▼ 40.90 (2.00%)
- Market Cap—
- Current Price₹ 2,003.90
- High / Low₹ 2,292 / 1,337
- Stock P/E61.6
- Book Value₹ 122
- Dividend Yield0.49 %
- ROCE29.0 %
- ROE27.40 %
- Face Value₹ 10.0
More figures (10)
- EPS (TTM)₹ 32.55
- Price / Book16.41
- OPM18.3 %
- Debt / Equity0.22
- Sales growth (3Y)16.6 %
- Profit growth (3Y)29.7 %
- Promoter holding77.6 %
- EV / EBITDA40.0
- Beta—
- All-time high₹ 2,292
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| CORONA | -6.52% | -2.95% | +27.25% | +44.70% | — | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- CORONA Remedies Limited is in the Drug Manufacturers - General industry (Healthcare).
- It trades at 61.6 times its last 12 months' earnings and 16.4 times book value.
- Revenue grew 16.6% a year over the last 3 years, profit 29.7% a year.
- Return on equity was 27.4% and return on capital employed 29.0% in the latest year.
- Debt was 0.22 times shareholders' equity.
- The share price is 12.6% below its 52-week high.
- Promoters and insiders hold about 77.6%; institutions about 19.8%.
Pros
AI- Strong return on equity: 25.1% on average over the last 3 years.
- Borrowings are moderate at 0.22 times shareholders' equity.
- Institutional (FII + DII) holding has risen by 12.1 points over 4 quarters.
- Promoters hold a large stake of 69.00%.
Cons
AI- Trades at 16.4 times its book value.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About CORONA Remedies Limited
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
- Employees
- 5,153
- Head office
- Ahmedabad
Peer comparison
| Company | Market cap (₹ Cr) | P/E | P/B | ROE | OPM | Sales CAGR | Div. yield |
|---|---|---|---|---|---|---|---|
| CORONA Remedies LimitedCORONA | — | 61.6 | 16.41 | 27.4% | 18.3% | +16.6% | 0.49% |
| Sai Parenteral's LimitedSAIPARENT | 2,153 | 168.0 | 3.25 | 21.1% | 6.4% | +126.1% | 0.00% |
Companies in the same industry (Drug Manufacturers - General). Tap a heading to sort. Sorting is a way to explore data, not a recommendation.
Quarterly Results
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
| ₹ Cr | Mar 2026 | TTM |
|---|---|---|
| Sales | 1,403 | 1,479 |
| 1,110 | 1,162 | |
| Material Cost % | 19% | 18% |
| Employee Cost % | 29% | 29% |
| Other Expenses % | 32% | 31% |
| Operating Profit | 293 | 317 |
| OPM % | 21% | 21% |
| 11 | 12 | |
| Exceptional items | -19 | -19 |
| Interest | 7 | 8 |
| Depreciation | 38 | 42 |
| Profit before tax | 240 | 260 |
| 23% | 23% | |
| Current tax | 51 | |
| Deferred tax | 4 | |
| 185 | 199 | |
| Profit from associates | 0 | |
| Profit to shareholders | 185 | 199 |
| EPS in Rs | 30.27 | 32.54 |
| Dividend Payout % | 24% |
Compounded Sales Growth
- TTM:
- 0%
Compounded Profit Growth
- TTM:
- 0%
Return on Equity
- 4 Years:
- 24%
- Last Year:
- 27%
| ₹ Cr | Mar 2026 | TTM |
|---|---|---|
| Sales | 1,403 | 1,479 |
| 1,110 | 1,162 | |
| Material Cost % | 19% | 18% |
| Employee Cost % | 29% | 29% |
| Other Expenses % | 32% | 31% |
| Operating Profit | 293 | 317 |
| OPM % | 21% | 21% |
| 11 | 12 | |
| Exceptional items | -19 | -19 |
| Interest | 7 | 8 |
| Depreciation | 38 | 42 |
| Profit before tax | 240 | 260 |
| 23% | 24% | |
| Current tax | 51 | |
| Deferred tax | 4 | |
| Net Profit | 185 | 199 |
| EPS in Rs | 30.22 | 32.47 |
| Dividend Payout % | 24% |
Compounded Sales Growth
- TTM:
- 0%
Compounded Profit Growth
- TTM:
- 0%
Return on Equity
- 4 Years:
- 24%
- Last Year:
- 27%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 61 | 61 | 61 | 61 |
| Reserves | 347 | 419 | 545 | 686 |
| 28 | 159 | 86 | 165 | |
| Long term borrowings | 67 | 16 | ||
| Short term borrowings | 2 | 67 | 47 | 143 |
| 159 | 191 | 237 | 293 | |
| Trade payables | 94 | 114 | 144 | 147 |
| Current liabilities | 137 | 224 | 240 | 361 |
| Total Liabilities | 595 | 831 | 930 | 1,205 |
| 257 | 319 | 393 | 438 | |
| Gross block | 286 | 360 | 446 | 506 |
| Accumulated depreciation | 29 | 41 | 53 | 68 |
| Goodwill & intangibles | 1 | 193 | 171 | 263 |
| CWIP | 73 | 128 | 194 | 147 |
| 264 | 384 | 343 | 621 | |
| Inventories | 105 | 98 | 129 | 125 |
| Trade receivables | 87 | 100 | 118 | 146 |
| Cash & equivalents | 14 | 3 | 3 | 2 |
| Current assets | 291 | 290 | 339 | 348 |
| Total Assets | 595 | 831 | 930 | 1,205 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 103 | 157 | 190 | 229 | |
| Profit for the year | 85 | 91 | 149 | 185 |
| Working capital changes | -5 | 9 | -17 | -6 |
| Direct taxes paid | -26 | -18 | -43 | -49 |
| -50 | -267 | -84 | -256 | |
| Fixed assets purchased | -95 | -286 | -92 | -174 |
| Fixed assets sold | 1 | 1 | 1 | 1 |
| Investments purchased | -17 | -90 | ||
| Investments sold | 55 | 14 | 3 | 0 |
| -45 | 99 | -107 | 25 | |
| Proceeds from borrowings | 180 | |||
| Repayment of borrowings | -32 | -77 | -51 | -36 |
| Interest paid | -4 | -14 | -10 | -7 |
| Dividends paid | -7 | -17 | -23 | -45 |
| Net Cash Flow | 8 | -11 | 0 | -1 |
| Free Cash Flow | 8 | -130 | 99 | 55 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROE | 20.8% | 20.4% | 27.5% | 27.4% |
| ROCE | 24.8% | 21.4% | 29.9% | 29.0% |
| Operating margin | 12.2% | 12.6% | 17.0% | 18.3% |
| Net margin | 9.6% | 8.9% | 12.5% | 13.2% |
| Debt / equity | 0.07 | 0.33 | 0.14 | 0.22 |
| Current ratio | 2.12 | 1.29 | 1.41 | 0.96 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities).
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 69.00%
- FIIs 4.21%
- DIIs 16.45%
- Public 10.34%
| % | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Promoters | 69.00% | 69.00% | 69.00% | 69.00% |
| 1.84% | 2.25% | 3.63% | 4.21% | |
| Foreign portfolio investors (Cat. I) | 1.83% | 2.07% | 2.81% | 3.34% |
| Foreign portfolio investors (Cat. II) | 0.01% | 0.18% | 0.82% | 0.87% |
| 6.76% | 7.02% | 12.90% | 16.45% | |
| Mutual funds | 6.38% | 6.35% | 12.50% | 16.06% |
| Insurance companies | 0.34% | 0.58% | 0.29% | 0.25% |
| Alternative investment funds | 0.05% | 0.09% | 0.11% | 0.13% |
| 22.40% | 21.74% | 14.48% | 10.34% | |
| Retail (up to ₹2 lakh) | 1.14% | 0.69% | 0.85% | 1.03% |
| HNIs (above ₹2 lakh) | 0.22% | 0.08% | 0.04% | |
| NRIs | 0.01% | 0.01% | 0.01% | 0.02% |
| Bodies corporate | 0.79% | 0.77% | 0.59% | 0.45% |
| No. of Shareholders | 31,035 | 19,609 | 20,185 | 21,098 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Documents
Announcements
- Certificate under SEBI (Depositories and Participants) Regulations, 2018CORONA Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 201805-Oct-2026
- Trading WindowCORONA Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201528-Sep-2026
- Spurt in VolumeSignificant increase in volume has been observed in CORONA Remedies Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and…09-Sep-2026
- UpdatesCORONA Remedies Limited has informed the Exchange regarding 'Machine Readable Financial results for Q1 2026-27'.07-Aug-2026
- Copy of Newspaper PublicationCORONA Remedies Limited has informed the Exchange about Copy of Newspaper Publication01-Aug-2026
- Investor PresentationCORONA Remedies Limited has informed the Exchange about Investor Presentation31-Jul-2026
- Press ReleaseCORONA Remedies Limited has informed the Exchange regarding a press release dated July 31, 2026, titled "Press Release on Unaudited financial results for Q1FY27".31-Jul-2026
- Outcome of Board MeetingCORONA Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.31-Jul-2026
- Shareholders meetingCORONA Remedies Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 09, 2026. Further, the company has informed the Exchange regard…10-Jul-2026
- Shareholders meetingCORONA Remedies Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 09, 202609-Jul-2026
- Certificate under SEBI (Depositories and Participants) Regulations, 2018CORONA Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 201806-Jul-2026
- Press ReleaseCORONA Remedies Limited has informed the Exchange regarding a press release dated Jun 30, 2026, titled "Press Release for Commencement of Commercial Production".30-Jun-2026
Annual reports
Credit ratings
Concalls & investor meets
- Analysts/Institutional Investor Meet/Con. Call UpdatesCORONA Remedies Limited has informed the Exchange about Schedule of meet16-Oct-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesCORONA Remedies Limited has informed the Exchange about Schedule of meet18-Sep-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesCORONA Remedies Limited has informed the Exchange about Schedule of meet20-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesCORONA Remedies Limited has informed the Exchange about Transcript10-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesCORONA Remedies Limited has informed the Exchange about Schedule of meet10-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesCORONA Remedies Limited has informed the Exchange about Link of Recording03-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesCORONA Remedies Limited has informed the Exchange about Schedule of meet22-Jul-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesCORONA Remedies Limited has informed the Exchange about Schedule of Analysts / Investor Conference10-Jun-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesCORONA Remedies Limited has informed the Exchange about Intimation of Non-Deal Roadshow03-Jun-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesCORONA Remedies Limited has informed the Exchange about Intimation for Non-Deal Roadshow01-Jun-2026
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 19 Jun 2026
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Questions about CORONA Remedies Limited
What is the share price of CORONA Remedies Limited today?
CORONA Remedies Limited (CORONA) last traded at ₹2,003.90 on NSE (16 Oct 2026, 3:30 PM IST). Prices may be delayed.
What is the market cap of CORONA Remedies Limited?
Not available right now.
What is the P/E ratio of CORONA Remedies Limited?
About 61.6 times its earnings over the last 12 months.
Is CORONA Remedies Limited a good investment?
We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.
How can I buy CORONA Remedies Limited shares?
You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.
Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).
Talk to us
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Experts are available Mon–Sat, 10 AM – 7 PM
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.